Stage II/III Colorectal Cancer Recurrence
Recruiting · NCT06314958 · Observational (researchers observe without assigning treatment) · Lead sponsor: City of Hope Medical Center
View the official record on ClinicalTrials.gov →Interventions studied
CENSURE
What this trial is about
This study will develop an assay to predict disease recurrence in patients with stage II/III CRC after receiving adjuvant chemotherapy, using genome-wide DNA methylation.
Who can take part
Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- Stage II (high-risk) or III colorectal cancer (TNM classification, 8th edition).
- Received standard diagnostic, staging, and therapeutic procedures as per local guidelines
- Received stage-specific curative-intent resection followed by adjuvant chemotherapy.
- Confirmed cancer-free survivorship confirmed at the time of study inclusion.
Exclusion criteria
- Lack of written informed consent.
- Development of recurrence in the first 6 months following adjuvant chemotherapy completion.
- Hereditary colorectal cancer syndromes (identified through genetic testing)
- Inflammatory bowel diseases
Where it is running
4 locations listed across 1 US state.
- City of Hope Medical Center - Monrovia, California, United States
- Barcelona University - Barcelona, Spain
- Second Affiliated Hospital of Dalian Medical University - Dalian, China
- La Paz University Hospital - Madrid, Spain